Form 8-K - Current report:
SEC Accession No. 0001213900-25-010731
Filing Date
2025-02-06
Accepted
2025-02-06 08:22:54
Documents
18
Period of Report
2025-02-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0230158-8k_cerotherap.htm   iXBRL 8-K 48004
2 PLACEMENT AGENCY AGREEMENT, DATED FEBRUARY 5, 2025 BY AND BETWEEN THE COMPANY AN ea023015801ex1-1_cerotherap.htm EX-1.1 95475
3 FORM OF COMMON WARRANT ea023015801ex4-1_cerotherap.htm EX-4.1 107540
4 FORM OF SECURITIES PURCHASE AGREEMENT BY AND BETWEEN THE COMPANY AND THE INVESTO ea023015801ex10-1_cerotherap.htm EX-10.1 221656
5 PRESS RELEASE (PRICING) DATED FEBRUARY 5, 2025 ea023015801ex99-1_cerotherap.htm EX-99.1 11294
  Complete submission text file 0001213900-25-010731.txt   825287

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cero-20250205.xsd EX-101.SCH 3798
7 XBRL DEFINITION FILE cero-20250205_def.xml EX-101.DEF 26673
8 XBRL LABEL FILE cero-20250205_lab.xml EX-101.LAB 36817
9 XBRL PRESENTATION FILE cero-20250205_pre.xml EX-101.PRE 25297
20 EXTRACTED XBRL INSTANCE DOCUMENT ea0230158-8k_cerotherap_htm.xml XML 5950
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

EIN.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40877 | Film No.: 25595559
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)